Search results for "Cooking"

showing 10 items of 635 documents

Behaviour of the neutrophil to lymphocyte ratio in young subjects with acute myocardial infarction

2016

In the last years the neutrophil to lymphocyte ratio (NLR) has been examined in cardiovascular disorders and in particular in coronary artery disease and acute myocardial infarction (AMI). Now we examined this parameter in subjects with juvenile myocardial infarction at the initial stage and after 3 and 12 months. We enrolled 123 young subjects (112 men and 11 women, mean age 39.4 ± 5.8 yrs) with AMI. The time interval between the AMI onset and the investigation was 13 ± 7 days. The mean value of NLR observed in young AMI subjects was significantly increased compared to normal controls (N = 1.817 ± 0.711; young AMI subjects = 2.376 ± 0.873, p <  0.0001). NLR does not discriminate STEMI (2.4…

MaleNeutrophilsPhysiologyLymphocyteMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematologyCoronary AngiographyCoronary artery diseaseLeukocyte Count0302 clinical medicineRetrospective StudieRisk FactorsMedicineLymphocytes030212 general & internal medicineMyocardial infarctionStage (cooking)HematologyNeutrophilSmokingJuvenile myocardial infarction; leukocyte count; neutrophil/lymphocyte ratio; Adult; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Humans; Inflammation; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myocardial Infarction; Neutrophils; Prognosis; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Smoking; Physiology; Hematology; Cardiology and Cardiovascular Medicine; Physiology (medical)HematologyMiddle AgedPrognosismedicine.anatomical_structureAbsolute neutrophil countCardiologyLymphocyteFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyPrognosi03 medical and health sciencesPhysiology (medical)Internal medicineHumansLymphocyte Countcardiovascular diseasesNeutrophil to lymphocyte ratioRetrospective StudiesInflammationbusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseJuvenile myocardial infarctionneutrophil/lymphocyte ratioST Elevation Myocardial InfarctionbusinessBiomarkersClinical Hemorheology and Microcirculation
researchProduct

Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma.

2016

Abstract Purpose To perform an external validation of the Assessment for Retreatment with Transarterial Chemoembolization (ART) and α-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC), Child–Pugh, and response (ABCR) scores and to compare them in terms of prognostic power. Materials and Methods From 2000 to 2015, 871 patients with hepatocellular carcinoma underwent transarterial chemoembolization at a tertiary referral hospital, and 176 met all inclusion and exclusion criteria for both scores and were analyzed. Nineteen percent (n = 34) had BCLC stage A disease and 81% had stage B disease. Thirty-nine patients (22%) presented with elevated AFP levels. Overall survival was calculated. …

MaleOncologyCancer ResearchMultivariate analysisKaplan-Meier EstimateGastroenterologyTertiary Care Centers0302 clinical medicineRisk FactorsMedicineStage (cooking)Aged 80 and overLiver NeoplasmsMiddle AgedTreatment OutcomeOncologyBrier score030220 oncology & carcinogenesisPredictive value of testsHepatocellular carcinomaRetreatmentInclusion and exclusion criteriaFemale030211 gastroenterology & hepatologyalpha-FetoproteinsCardiology and Cardiovascular MedicineAlpha-fetoproteinLiver cancerAdultmedicine.medical_specialtyTreatment responseCarcinoma HepatocellularClinical Decision-MakingTertiary referral hospitalRisk AssessmentDecision Support TechniquesYoung Adult03 medical and health sciencesPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingAspartate AminotransferasesChemoembolization TherapeuticAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryPatient SelectionExternal validationReproducibility of ResultsRetrospective cohort studymedicine.diseaseConfidence intervalBCLC Stagedigestive system diseasesSurgerybusinessJournal of Clinical Oncology
researchProduct

DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma:…

2001

BACKGROUND The prognostic value of DNA ploidy, S-phase fraction (SPF) and K-ras-2 mutations in gastric carcinoma (GC) has not yet been clearly defined. The aim of this study was to clarify the association between biomolecular variables, tumor characteristics, and clinical outcome in GC patients. METHODS Resected specimens from a consecutive series of 69 patients with GC who underwent potentially curative surgery were studied prospectively. DNA ploidy and SPF were assessed by flow cytometry on multiple frozen tumor samples, whereas K-ras-2 mutations were detected by polymerase chain reaction followed by single-strand conformation polymorphism. All the patients involved in this study were fol…

MaleOncologyCancer ResearchPathologyStagingSettore MED/06 - Oncologia MedicaAneuploidyPolymerase Chain ReactionS Phaselaw.inventionRisk FactorslawProspective StudiesStage (cooking)Prospective cohort studyK-ras-2Polymorphism Single-Stranded ConformationalPolymerase chain reactionUnivariate analysisDNA NeoplasmMiddle AgedFlow CytometryPrognosisOncologyFemaleAdultmedicine.medical_specialtyPrognosiGastrectomyPredictive Value of TestsStomach NeoplasmsInternal medicineBiomarkers TumorCarcinomamedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm Stagingbusiness.industryCarcinomaGastric carcinomaCancerAneuploidymedicine.diseaseSurvival AnalysisGenes rasDNA ploidyNeoplasm Recurrence LocalbusinessS-phase fraction
researchProduct

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, …

2005

Purpose The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to evaluate the possible associations between specific TP53 mutations and tumor site, and to evaluate the prognostic and predictive significance of these mutations in different site, stage, and treatment subgroups. Patients and Methods A total of 3,583 CRC patients from 25 different research groups in 17 countries were recruited to the study. Patients were divided into three groups according to site of the primary tumor. TP53 mutational analyses spanned exons 4 to 8. Results TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal colon and rectal tumors. They were assoc…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyRECTAL-CARCINOMATumor suppressor geneColorectal cancerLymphovascular invasionMICROSATELLITE INSTABILITYCELL LUNG-CANCERDNA Mutational AnalysisALLELIC LOSSDUKES STAGE-BMOLECULAR MARKERSInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseNeoplasm InvasivenessStage (cooking)neoplasmsSurvival rateAgedNeoplasm Stagingbusiness.industryCOLON-CANCERMicrosatellite instabilityZINC-BINDING DOMAINExonsMiddle AgedWILD-TYPE P53medicine.diseaseAdenocarcinoma MucinousPrimary tumorSurvival RateOncologyChemotherapy AdjuvantMutationAdenocarcinomaFemaleZINC-BINDING DOMAIN; CELL LUNG-CANCER; DUKES STAGE-B; WILD-TYPE P53; GENETIC PATHWAYS; COLON-CANCER; MICROSATELLITE INSTABILITY; MOLECULAR MARKERS; RECTAL-CARCINOMA; ALLELIC LOSSGENETIC PATHWAYSTumor Suppressor Protein p53Colorectal NeoplasmsbusinessFollow-Up Studies
researchProduct

Survival of Patients with Oral Cavity Cancer in Germany

2012

The purpose of the present study was to describe the survival of patients diagnosed with oral cavity cancer in Germany. The analyses relied on data from eleven population-based cancer registries in Germany covering a population of 33 million inhabitants. Patients with a diagnosis of oral cavity cancer (ICD-10: C00-06) between 1997 and 2006 are included. Period analysis for 2002-2006 was applied to estimate five-year age-standardized relative survival, taking into account patients' sex as well as grade and tumor stage. Overall five-year relative survival for oral cavity cancer patients was 54.6%. According to tumor localization, five-year survival was 86.5% for lip cancer, 48.1% for tongue c…

MaleOncologyHealth ScreeningDatabases FactualEpidemiologyOral Mucosal CancersOral DiseasesGermanyStage (cooking)Young adultSkin TumorsMouth neoplasmeducation.field_of_studyMultidisciplinaryRelative survivalQRMiddle Agedmedicine.anatomical_structureOncologyHead and Neck SurgeryMedicineFemaleMouth NeoplasmsPublic HealthAlcoholCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyTobacco ControlAdolescentScienceOral MedicinePopulationYoung AdultTongueInternal medicinemedicineHumanseducationSurvival analysisAgedbusiness.industryCancers and NeoplasmsCancermedicine.diseaseSurvival AnalysisSurgeryDentistrySurgeryPreventive MedicinebusinessPLoS ONE
researchProduct

A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.

2010

Summary Background Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions. The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers. Methods The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries. Data were collected using a standardized procedure. Results Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.…

MaleOncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPerforation (oil well)Population[SDV.CAN]Life Sciences [q-bio]/CancerAdenocarcinomaSampling Studies[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRegistries030212 general & internal medicineStage (cooking)educationAgedAged 80 and overPatient Care TeamChemotherapyeducation.field_of_studybusiness.industryAge FactorsGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.disease3. Good healthSurgeryClinical trialChemotherapy AdjuvantIntestinal Perforation030220 oncology & carcinogenesisColonic NeoplasmsMultivariate AnalysisPopulation studyFemaleFrancebusinessIntestinal Obstruction
researchProduct

Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papil…

2019

Objectives: To investigate the expression of several immunohistochemical (IHC) markers and their predictive ability for the recurrence-free and progression-free survival of papillary urothelial bladder cancer (UBC) pTa/pT1 G2 (WHO 1973) compared to classical anatomo-clinical variables using a multidimensional analysis. Materials and Methods: A population-based cohort of 213 primary stage UBC (pTa/pT1) G2 (WHO 1973) was evaluated by classic anatomopathological variables and characterized by immunohistochemistry (23 IHC markers, representative of different oncogenic pathways). The most important variables as a predictor of recurrence-free and progression-free survival were selected using mult…

MaleOncologymedicine.medical_specialtyMultidimensional analysisSurvivinUrologyPopulation030232 urology & nephrologyCohort Studies03 medical and health sciences0302 clinical medicineCyclin D1Stage Ta/T1Predictive Value of TestsInternal medicineSurvivinBiomarkers TumormedicineHumansCyclin D1Progression-free survivalStage (cooking)educationCyclin-Dependent Kinase Inhibitor p16AgedNeoplasm Stagingeducation.field_of_studyBladder cancerbiologybusiness.industryClinical outcomeBladder cancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma PapillarySurvival RateKi-67 AntigenUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisKi-67biology.proteinImmunohistochemistryFemaleNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials

2021

BACKGROUND Ten-year survival rates in mycosis fungoides (MF) broadly varies, however, there is no standardized prognostic index available. This is presumably due to low prevalence, heterogeneity, and diagnostic challenges in MF. Recent studies have focused on identifying objective prognostic indices by using different parameters for survival determinants. The Cutaneous Lymphoma International Prognostic Index (CLIPI) and the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) represent prototypical studies that identify prognostic factors, seeking to improve management and outcomes in early-stage MF. Detecting these factors and stratifying MF patients according to their …

MaleOncologymedicine.medical_specialtySkin Neoplasms610 MedizinDermatologyDiseaseCutaneous lymphomaMycosis FungoidesInternational Prognostic IndexInternal medicine610 Medical sciencesmedicineHumansProspective StudiesStage (cooking)Neoplasm StagingMycosis fungoidesbusiness.industryLarge cellPrognosismedicine.diseaseLymphomaT-stageFemalebusiness
researchProduct

Malignant lymphoma of the oral cavity and the maxillofacial region: overall survival prognostic factors

2013

Objective: To identify the overall survival and prognostic factors of malignant lymphoma of the oral cavity and the maxillofacial region. Study Design: Clinical records data were obtained in order to determine overall survival at 2 and 5 years, the individual survival percentage of each possible prognostic factor with the actuarial technique, and the survival regarding the possible prognostic factors with the actuarial technique and the Log-rank and Cox's regression tests. Results: Of 151 subjects, an overall survival was 60% at 2 years, and 45% at 5 years. The multivariate analysis demonstrated statistically significant differences for clinical stage (p=0.002), extranodal involvement (p=0.…

MaleOncologymedicine.medical_specialtyTime FactorsMultivariate analysisLymphomaCross-sectional studyOdontologíasurvivalInternal medicinemedicineHumansStage (cooking)Extranodal InvolvementGeneral DentistrySurvival rateAgedRetrospective StudiesMaxillary NeoplasmsMouth neoplasmOral Medicine and Pathologybusiness.industryRetrospective cohort studyMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Prognosismedicine.disease//purl.org/pe-repo/ocde/ford#3.02.14 [https]Ciencias de la saludSurgeryLymphomaSurvival RateCross-Sectional StudiesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASoral cavityResearch-ArticleFemaleMouth NeoplasmsSurgerybusiness
researchProduct

Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based …

2021

Purpose of review To investigate the features and optimal management of pN+ cM0 prostate cancer (PCa) according to registry-based studies. Recent findings Up to 15% of PCa patients harbor lymph node invasion (pN+) at radical prostatectomy plus lymph node dissection. Nonetheless, the optimal management strategy in this setting is not well characterized. Summary We performed a systematic review including n = 13 studies. Management strategies comprised 13 536 men undergoing observation, 11 149 adjuvant androgen deprivation therapy (aADT), 7,075 adjuvant radiotherapy (aRT) +aADT and 705 aRT. Baseline features showed aggressive PCa in the majority of men. At a median follow-up ranging 48-134mont…

MaleOncologymedicine.medical_specialtyUrologymedicine.medical_treatmentMedizinpopulation-based studiespositive nodesAndrogen deprivation therapyProstate cancerQuality of lifeInternal medicineHumansMedicineStage (cooking)Lymph nodeAdjuvantNeoplasm StagingRetrospective StudiesProstatectomyRadiotherapybusiness.industryProstatectomyProstatic NeoplasmsAndrogen Antagonistslymph nodeProstate-Specific Antigenprostate cancermedicine.diseaseradical prostatectomyProstate-specific antigenmedicine.anatomical_structurelymph node; population-based studies; positive nodes; prostate cancer; radical prostatectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Quality of Life; Radiotherapy Adjuvant; Retrospective Studies; Androgen Antagonists; Prostatic NeoplasmsLymphatic MetastasisQuality of LifeLymph Node ExcisionRadiotherapy AdjuvantLymphadenectomyLymph node; Population-based studies; Positive nodes; Prostate cancer; Radical prostatectomybusinessCurrent Opinion in Urology
researchProduct